Side effects are similar to those of otherbeta blockers, such as bronchoconstriction, cardiac failure, cold extremities, fatigue and depression, hypoglycaemia.[1]
After its introduction, keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients.[3]
A synthesis is available which relates the absolute configuration of the more potent optical isomer to (+)-lactic acid. The glycerol derivative (2) is available from D-mannitol and retains optical activity as the two 1° alcohol functions are differentially protected. Displacement with sodium p-acetamidophenoxide (1, deprotonated paracetamol) gives3 which is deprotected with dilute acid, the primary alcohol function is selectively reacted with one molar equivalent oftosyl chloride and pyridine, then treated with NaOH indimethylsulfoxide to yield3. Epoxide opening withisopropylamine leads to optically active prolactolol (4).[citation needed]
The compound was studied by scientists at the Research Department of theICI Pharmaceuticals Division inAlderley Park with physiologists at theUniversity of Leeds in the early 1970s when it was known as compoundICI 66082; they utilised dogs, cats and rats in their investigations. Earlier research had also been carried out as early as 1967 on this and similar molecules by other research teams also with ICI.[9][10]
^Mannhold R (February 2005). "The impact of lipophilicity in drug research: a case report on beta-blockers".Mini Rev Med Chem.5 (2):197–205.doi:10.2174/1389557053402701.PMID15720289.
^Danilewicz JC, Kemp JE (February 1973). "Absolute configuration by asymmetric synthesis of (+)-1-(4-acetamidophenoxy)-3-(isopropylamino)-propan-z-ol (practolol)".Journal of Medicinal Chemistry.16 (2):168–169.doi:10.1021/jm00260a020.PMID4405110.
^"Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived fromthe original on 2015-02-21. Retrieved2013-09-17.
N
Y (what is this?) (verify)